FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047492039> ?p ?o ?g. }

• W3047492039 endingPage "e038911" @default.
• W3047492039 startingPage "e038911" @default.
• W3047492039 abstract "Introduction There are no disease-modifying treatments for Parkinson’s disease (PD). We undertook the first drug screen in PD patient tissue and idntified ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims of this trial are to determine safety and tolerability of UDCA in PD at 30 mg/kg, confirm the target engagement of UDCA, apply a novel motion sensor-based approach to quantify disease progression objectively, and estimate the mean effect size and its variance on the change in motor severity. Methods and analysis This is a phase II, two-centre, double-blind, randomised, placebo-controlled trial of UDCA at a dose of 30 mg/kg in 30 participants with early PD. Treatment duration is 48 weeks, followed by an 8-week washout phase. Randomisation is 2:1, drug to placebo. Assessments are performed at baseline, week 12, 24, 36, 48 and 56. The primary outcome is safety and tolerability. Secondary outcomes will compare the change between baseline and week 48 using the following three approaches: the Movement Disorders Society Unified Parkinson’s Disease Rating Scale Part 3 in the practically defined ‘OFF’ medication state; confirmation of target engagement, applying 31 Phosphorus MR Spectroscopy to assess the levels of ATP and relevant metabolites in the brain; and objective quantification of motor impairment, using a validated, motion sensor-based approach. The primary outcome will be reported using descriptive statistics and comparisons between treatment groups. For each secondary outcome, the change from baseline will be summarised within treatment groups using summary statistics and appropriate statistical tests assessing for significant differences. All outcomes will use an intention-to-treat analysis population. Ethics and dissemination This trial has been approved by the East of England – Cambridgeshire and Hertfordshire Research Ethics committee. Results will be disseminated in peer-reviewed journals, presentations at scientific meetings and to patients in a lay-summary format. Trial registration number NCT03840005 ." @default.
• W3047492039 created "2020-08-10" @default.
• W3047492039 creator A5004946574 @default.
• W3047492039 creator A5011132611 @default.
• W3047492039 creator A5026621001 @default.
• W3047492039 creator A5031389008 @default.
• W3047492039 creator A5040064830 @default.
• W3047492039 creator A5048644893 @default.
• W3047492039 creator A5066163857 @default.
• W3047492039 creator A5070983118 @default.
• W3047492039 creator A5074142639 @default.
• W3047492039 creator A5075012158 @default.
• W3047492039 creator A5076050363 @default.
• W3047492039 creator A5080425407 @default.
• W3047492039 creator A5083847551 @default.
• W3047492039 creator A5090252124 @default.
• W3047492039 creator A5091746433 @default.
• W3047492039 date "2020-08-01" @default.
• W3047492039 modified "2023-10-15" @default.
• W3047492039 title "Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study" @default.
• W3047492039 cites W1561072761 @default.
• W3047492039 cites W1974704788 @default.
• W3047492039 cites W1976325983 @default.
• W3047492039 cites W1976350579 @default.
• W3047492039 cites W1977040584 @default.
• W3047492039 cites W1980089776 @default.
• W3047492039 cites W1996271059 @default.
• W3047492039 cites W2000073596 @default.
• W3047492039 cites W2007627153 @default.
• W3047492039 cites W2008560062 @default.
• W3047492039 cites W2015482578 @default.
• W3047492039 cites W2034424279 @default.
• W3047492039 cites W2040456345 @default.
• W3047492039 cites W2055619740 @default.
• W3047492039 cites W2062229924 @default.
• W3047492039 cites W2070159246 @default.
• W3047492039 cites W2080090092 @default.
• W3047492039 cites W2084140068 @default.
• W3047492039 cites W2085091329 @default.
• W3047492039 cites W2089085990 @default.
• W3047492039 cites W2091788949 @default.
• W3047492039 cites W2106045149 @default.
• W3047492039 cites W2122703782 @default.
• W3047492039 cites W2129615716 @default.
• W3047492039 cites W2131823335 @default.
• W3047492039 cites W2140978740 @default.
• W3047492039 cites W2147111512 @default.
• W3047492039 cites W2165758561 @default.
• W3047492039 cites W2168946626 @default.
• W3047492039 cites W2178282635 @default.
• W3047492039 cites W2279055345 @default.
• W3047492039 cites W2304742949 @default.
• W3047492039 cites W2344090596 @default.
• W3047492039 cites W2400519479 @default.
• W3047492039 cites W2417395660 @default.
• W3047492039 cites W2465612755 @default.
• W3047492039 cites W2554960300 @default.
• W3047492039 cites W2615261953 @default.
• W3047492039 cites W2744843428 @default.
• W3047492039 cites W2749718288 @default.
• W3047492039 cites W2756938911 @default.
• W3047492039 cites W2792355252 @default.
• W3047492039 cites W2914029965 @default.
• W3047492039 cites W2998744670 @default.
• W3047492039 cites W3006385761 @default.
• W3047492039 cites W4211123396 @default.
• W3047492039 doi "https://doi.org/10.1136/bmjopen-2020-038911" @default.
• W3047492039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7409998" @default.
• W3047492039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32759251" @default.
• W3047492039 hasPublicationYear "2020" @default.
• W3047492039 type Work @default.
• W3047492039 sameAs 3047492039 @default.
• W3047492039 citedByCount "16" @default.
• W3047492039 countsByYear W30474920392021 @default.
• W3047492039 countsByYear W30474920392022 @default.
• W3047492039 countsByYear W30474920392023 @default.
• W3047492039 crossrefType "journal-article" @default.
• W3047492039 hasAuthorship W3047492039A5004946574 @default.
• W3047492039 hasAuthorship W3047492039A5011132611 @default.
• W3047492039 hasAuthorship W3047492039A5026621001 @default.
• W3047492039 hasAuthorship W3047492039A5031389008 @default.
• W3047492039 hasAuthorship W3047492039A5040064830 @default.
• W3047492039 hasAuthorship W3047492039A5048644893 @default.
• W3047492039 hasAuthorship W3047492039A5066163857 @default.
• W3047492039 hasAuthorship W3047492039A5070983118 @default.
• W3047492039 hasAuthorship W3047492039A5074142639 @default.
• W3047492039 hasAuthorship W3047492039A5075012158 @default.
• W3047492039 hasAuthorship W3047492039A5076050363 @default.
• W3047492039 hasAuthorship W3047492039A5080425407 @default.
• W3047492039 hasAuthorship W3047492039A5083847551 @default.
• W3047492039 hasAuthorship W3047492039A5090252124 @default.
• W3047492039 hasAuthorship W3047492039A5091746433 @default.
• W3047492039 hasBestOaLocation W30474920391 @default.
• W3047492039 hasConcept C126322002 @default.
• W3047492039 hasConcept C142724271 @default.
• W3047492039 hasConcept C197934379 @default.
• W3047492039 hasConcept C204787440 @default.
• W3047492039 hasConcept C27081682 @default.

• next